- $9.77bn
- $9.55bn
- $507.44m
Glaukos up after FDA accepts marketing application for eye implant
Brief: Glaukos Announces FDA Acceptance Of NDA Submission For Idose Tr
Brief: Glaukos sees FY sales USD 295-300 million
Glaukos Corp reports results for the quarter ended in March - Earnings Summary
Brief: Glaukos Announces First Quarter 2023 Financial Results
Glaukos Corp expected to post a loss of 58 cents a share - Earnings Preview
Brief: Glaukos Submits New Drug Application To U.S. FDA For IDose TR
U.S. RESEARCH ROUNDUP-Cinemark Holdings, Commercial Metals Co, Nvidia
Glaukos Corp reports results for the quarter ended in December - Earnings Summary
Glaukos Corp expected to post a loss of 55 cents a share - Earnings Preview
Brief: Glaukos Announces Results For Idose TR Exchange Trial
Brief: Glaukos Announces Clinical Updates For Several Corneal Health Pipeline Programs
U.S. RESEARCH ROUNDUP-FedEx, Glaukos, Teleflex
U.S. RESEARCH ROUNDUP-Glaukos, Invesco, Moderna
Medical device makers may see recovery in 2023 - Citi
U.S. RESEARCH ROUNDUP-ACI Worldwide, Kaman, Sinclair Broadcast Group
Brief: Glaukos Corporation Announces Q3 2022 Financial Results
Glaukos Corp reports results for the quarter ended in September - Earnings Summary
Glaukos Corp expected to post a loss of 52 cents a share - Earnings Preview